Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
63
-
Total 13F shares, excl. options
-
45.2M
-
Shares change
-
-1.49M
-
Total reported value, excl. options
-
$28.7M
-
Value change
-
-$1.51M
-
Put/Call ratio
-
5.38
-
Number of buys
-
25
-
Number of sells
-
-35
-
Price
-
$0.64
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q1 2025
76 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q1 2025.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 63 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45.2M shares
of 166M outstanding shares and own 27.29% of the company stock.
Largest 10 shareholders include TANG CAPITAL MANAGEMENT LLC (6.72M shares), BVF INC/IL (5.23M shares), VANGUARD GROUP INC (5.12M shares), Prosight Management, LP (3.93M shares), ACADIAN ASSET MANAGEMENT LLC (3.23M shares), MILLENNIUM MANAGEMENT LLC (2.83M shares), Point72 Asset Management, L.P. (2.65M shares), Woodline Partners LP (1.66M shares), Laurion Capital Management LP (1.29M shares), and BlackRock, Inc. (1.17M shares).
This table shows the top 63 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.